Source:

Press Release

March 07, 2022
1 min read
Save

Updated guidelines address antirheumatic medication in patients undergoing THA, TKA

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The American College of Rheumatology and the American Association of Hip and Knee Surgeons have released updated recommendations for the perioperative management of antirheumatic medication in patients undergoing hip and knee arthroplasty.

The guidelines, which are an update to the 2017 recommendations, are designed to help physicians and health care providers address disease-modifying medications for adults undergoing elective total hip or total knee arthroplasties with rheumatic diseases, such as inflammatory arthritis and systemic lupus erythematosus (SLE).

Guidelines
Source: Adobe Stock

The updated guideline summary addresses rituximab, belimumab, anifrolumab and voclosporin for patients with severe SLE, as well as ixekizumab and guselkumab for patients with spondyloarthritis. The guidelines also include recently introduced immunosuppressive medications and new recommendations for the management of Janus kinase inhibitors.

According to the release, the full manuscript will be submitted for publication in Arthritis & Rheumatology and Arthritis Care & Research in the summer of 2022.

Reference:

https://www.rheumatology.org/Portals/0/Files/Perioperative-Management-Guideline-Summary.pdf